Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)

NCT01953536 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Vintafolide 2.5 mg
DRUG: Paclitaxel 80 mg/m^2
DRUG: Etarfolatide
DRUG: Folic acid
DRUG: Premedication for Paclitaxel

Sponsor

Endocyte